布比卡因(Bupivacaine) - 药物靶点：SCNA_在研适应症：术后疼痛，恶心，疼痛_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Extended-release formulation of bupivacaine(Sonoran Biosciences)、丁哌卡因、AH 250

+ [11]

靶点

SCNA

作用机制

SCNA阻滞剂(钠通道α亚基家族阻滞剂)

治疗领域

神经系统疾病其他疾病

在研适应症

术后疼痛恶心疼痛+ [2]

非在研适应症

关节强直拇囊炎冠心病+ [13]

原研机构

Pacira Biosciences, Inc.

在研机构

江苏恒瑞医药股份有限公司Pacira Ireland Ltd.

Pacira Biosciences, Inc.

+ [3]

非在研机构

Pacira Ltd.

最高研发阶段批准上市

首次获批日期

欧盟 (2020-11-16),

术后疼痛

最高研发阶段(中国)批准上市

特殊审评突破性疗法 (美国)、孤儿药 (美国)

登录后查看时间轴

结构/序列

分子式C18H28N2O

InChIKeyLEBVLXFERQHONN-UHFFFAOYSA-N

CAS号38396-39-3

关联

1,663

项与布比卡因相关的临床试验

NCT05785377

/ Not yet recruitingN/AIIT

Efficacy of Neostigmine as an Adjuvant to Bupivacaine in Ultrasound-guided Transversus Abdominis Plane Block as a Postoperative Analgesia After Caesarean Delivery.

Cesarean birth is a common surgical procedure. After cesarean birth, postsurgical pain may delay recovery, interfere with maternal-newborn bonding, and reduce the breastfeeding if not adequately controlled. Postpartum analgesia has become a common concern.
Many adjuvant drugs used for peripheral nerve blocks as( N-methyl-d-aspartate (NMDA) receptor antagonists , Magnesium , Ephedrine , Dexamesathone , Fentanyl , Midazolam and Neostigmine) The potential of neostigmine as an adjuvant in peripheral nerve block is through its action to increase acetylcholine at muscarinic junctions of peripheral nerves. 500 mcg neostigmine was used as adjuvant to local anesthetic in an axillary brachial plexus block leads to decreased pain and less use of analgesics in the first 24 hours postoperatively with no incidence of adverse effects.

开始日期2025-12-01

申办/合作机构

Mansoura University

NCT04168710

/ Not yet recruiting临床1/2期IIT

Ultrasound Guided Emergency Physician Performed Erector Spinae Nerve Block for Rib Fracture Analgesia

The study will be a prospective randomized double blinded placebo controlled clinical trial using ultrasound guided erector spinae plane block as an analgesic adjunct among adult emergency department (ED) patients with rib fractures using mean morphine milligram equivalents as the primary outcome.

开始日期2025-05-01

申办/合作机构

Yale University

NCT06736392

/ Not yet recruiting临床2期IIT

Efficacy of Dexmedetomidine As an Adjuvant to Bupivacaine in Ultrasound Guided Pericapsular Nerve Group Block for Postoperative Analgesia During Spinal Anesthesia in Hip Replacement Surgeries, a Randomized Controlled Study

Our aim will be to investigate the efficacy of dexmedetomidine as an adjuvant to bupivacaine in ultrasound guided pericapsular nerve group (PENG) block for postoperative analgesia in hip replacement surgeries.
* Our primary outcome of the study: total amount of postoperative morphine consumption in the first 24h postoperative.
* Our secondary outcome of the study: postoperative analgesia assessed by pain score (by Visual Analog Scale)

开始日期2025-03-01

申办/合作机构

Assiut University

100 项与布比卡因相关的临床结果

登录后查看更多信息

100 项与布比卡因相关的转化医学

登录后查看更多信息

100 项与布比卡因相关的专利（医药）

登录后查看更多信息

17,676

项与布比卡因相关的文献（医药）

2025-12-01·Current Pain and Headache Reports

Rhomboid Intercostal and Subserratus Plane Block for Acute Pain Management after Abdominal Surgeries: A Narrative Review

Review

作者: Ly, Gianni H ; Dorius, Bradley ; Boullion, Jolie A ; Kaye, Alan D ; Shekoohi, Sahar ; Patel, Hirni ; Robinson, Christopher L ; Rogers, Brianna N ; Ahmadzadeh, Shahab ; Thomassen, Austin S ; Hollander, Alex V

PURPOSE OF REVIEW:

The rhomboid intercostal and subserratus plane (RISS) block is an effective, safer alternative for managing postoperative acute pain following abdominal surgeries. The RISS block offers several advantages over traditional approaches, including reduced incidence of puncture-related complications, lower rates of systemic opioid consumption, and more consistent analgesic coverage of lower thoracic dermatomes.

RECENT FINDINGS:

Despite a favorable safety profile, the RISS block carries potential risks, such as pneumothorax and local anesthetic systemic toxicity, particularly when long-acting anesthetics such as bupivacaine or ropivacaine are used. Careful administration with ultrasound guidance minimizes these risks, enhancing patient safety. Compared to epidural and paravertebral blocks, RISS is associated with fewer instances of nerve damage, hemodynamic instability, and bleeding. Research suggests that RISS not only improves postoperative pain scores, but also extends duration of analgesic effect, reducing total opioid use by nearly 40%.

CONCLUSION:

Future directions include clinical trials to validate efficacy across diverse patient populations, comparative studies with other regional blocks, and evaluations of long-term outcomes. Expanding our understanding of RISS block application may help advance multimodal pain management protocols, underscoring potential to improve recovery, reduce opioid dependency, and elevate patient quality of life in postoperative settings.

2025-03-01·JPRAS open

Efficacy of pectoralis nerve blocks I & II with liposomal bupivacaine in patients undergoing elective breast reduction procedures: A retrospective study

Article

作者: Kazior, Michael ; Karmarkar, Amol ; Klumb, Ivette ; Sanghvi, Anup Palak ; Kanani, Charmi

Background:

The pectoral nerve (PECs) block I and II nerve blocks with liposomal bupivacaine (LB, Exparel) are used for postoperative analgesia in breast surgery, but evidence on efficacy for breast reduction is limited. We examined the effect of the PECS I and II blocks with LB on perioperative opioid use and pain scores compared to no block and blocks with plain local anesthetic (LA). We hypothesized that patients receiving a block with LB would require lower opioid amounts.

Methods:

This retrospective cohort analysis included 120 patients undergoing breast reduction from 2011-2023. Patients received: no block, PECs block with plain LA, or PECs block with LB. Primary outcomes were intraoperative, Post-Anesthesia Care Unit (PACU), and outpatient opioid requirements. The secondary outcomes were PACU pain scores.

Results:

Forty patients had no block, twenty-six received plain LA block, and fifty-four received LB block. For intraoperative opioids, LB block significantly lowered use compared to no block. PACU opioid use showed no differences between groups. For outpatient opioids, both LB and plain LA blocks significantly lowered use compared to no block. No significant pain score differences were found between groups.

Conclusions:

Patients receiving the PECS block had decreased outpatient narcotic requirements compared to those patients who did not get the block. Patients receiving PECS block with LB had the further benefit of having decreased intraoperative narcotic requirements compared to the other groups. This highlights the potential benefit of performing the PECS block for patients undergoing breast reduction surgery.

2025-03-01·Interventional Pain Medicine

Percutaneous pulsed radiofrequency treatment of the splanchnic nerves for chronic flank pain secondary to non-obstructive nephrolithiasis

Article

作者: Kim, Edward ; Banik, Ratan K

Chronic benign flank pain of unknown etiology presents a significant challenge for pain physicians, especially when interventional treatment options are limited. We report the case of a 26-year-old male with a history of chronic left flank pain, recurrent non-obstructing nephrolithiasis, and a complex urologic background, who was referred to pain management after failing to find relief through previous urologic interventions. Despite the absence of new obstructing stones, the patient's pain persisted. Initial splanchnic nerve blocks using 0.25 % bupivacaine and dexamethasone provided temporary relief, leading to the decision to proceed with pulsed radiofrequency (RF) treatment of the left splanchnic nerves. Under fluoroscopic guidance, the pulsed RF procedure resulted in significant pain reduction, which lasted for four to six months. Over the course of four years, the procedure was repeated six times, providing sustained relief and allowing the patient to resume normal activities, including school and work. This case highlights the potential effectiveness of pulsed RF as a viable option for managing refractory chronic flank pain when other treatments have failed.

286

项与布比卡因相关的新闻（医药）

2025-02-07

·PRNewswire

Shareholders that lost money on Pacira BioSciences, Inc.(PCRX) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More

NEW YORK, Feb. 7, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Pacira BioSciences, Inc. ("Pacira" or the "Company") (NASDAQ: PCRX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Pacira investors who were adversely affected by alleged securities fraud between August 2, 2023 and August 8, 2024. Follow the link below to get more information and be contacted by a member of our team: PCRX investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500. CASE DETAILS: According to the complaint, on August 9, 2024, Pacira issued a press release announcing the results of its lawsuit against eVenus for patent infringement. Pacira disclosed that the court "found that the company's U.S. Patent No. 11,033,495 (the '495 patent) is not valid," and, thus, eVenus is not infringing on anything. Pacira's '495 patent is for Exparel, which is the main source of growth for the Company, encapsulating roughly 80% of its revenue. Analysts have noted that the invalidity of the '495 patent calls into question the validity of the Company's other patents, potentially resulting in more generic entrants into the market and increased litigation expenses moving forward. Following this news, Pacira's common stock declined dramatically. From a closing market price of $22.36 per share on August 8, 2024, Pacira's stock price fell to a low of $11.70 per share on August 9, 2024, a decline of over 47% in a single day. WHAT'S NEXT? If you suffered a loss in Pacira during the relevant time frame, you have until March 14, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate. WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. Ed Korsinsky, Esq. 33 Whitehall Street, 17th Floor New York, NY 10004 [email protected] Tel: (212) 363-7500 Fax: (212) 363-7171 SOURCE Levi & Korsinsky, LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

专利侵权

2025-01-31

·Business Wire

Virpax's Matthew Barnes to Present at Outsourcing in Clinical Trials Conference

BERWYN, Pa.--( BUSINESS WIRE )-- Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”) , a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral barrier indications, is pleased to announce its senior director of portfolio management, Matthew Barnes, will be presenting at Outsourcing in Clinical Trial Conference. The Outsourcing in Clinical Trials (OCT) is a leading conference series for the clinical trial community that takes place worldwide and brings together 1,000+ industry leaders every year to share their success stories and discuss solutions for accelerating clinical trial timelines while maintaining reasonable costs. OCT Series offers a valuable hub for biotech and pharma companies as well as trial sponsors, medical device manufacturers, and solution providers to safely collaborate, connect, and work towards success in their clinical trials. In addition, the Company would like to congratulate Dr. Sheila Mathias, our Chief Scientific Officer, and Matthew Barnes on two articles that they published in the first DIA (Drug Information Association) Global Forum and an additional article that they published in Outsourcing In Clinical Trials (OCT) Handbook 2025. About Virpax Pharmaceuticals Virpax is developing branded, non-addictive pain management products candidates using its proprietary technologies to optimize and target drug delivery. Virpax is initially seeking FDA approval for two prescription drug candidates that employ two different patented drug delivery platforms. Probudur™ is a single injection liposomal bupivacaine formulation being developed to manage post-operative pain and Envelta™ is an intranasal molecular envelope enkephalin formulation being developed to manage acute and chronic pain, including pain associated with cancer. Virpax is also using its intranasal Molecular Envelope Technology (MET) to develop one other prescription product candidate, NobrXiol™, which is being developed for the nasal delivery of a pharmaceutical-grade cannabidiol (CBD) for the management of rare pediatric epilepsy. Virpax has competitive cooperative research and development agreements (CRADAs) for two of its prescription drug candidates, one with the National Institutes of Health (NIH) and one with the Department of Defense (DOD). Virpax is also seeking partners for two nonprescription product candidates: AnQlar, which is being developed to inhibit viral replication caused by influenza or SARS-CoV-2, and Epoladerm™, which is a topical diclofenac spray film formulation being developed to manage pain associated with osteoarthritis. For more information, please visit https://www.virpaxpharma.com and follow us on Twitter, LinkedIn and YouTube. Forward-Looking Statements This press release contains certain forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, as amended, including those described below. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions. These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events and involve known and unknown risks, uncertainties, and other factors, including the additional capital which will be necessary to complete studies and clinical trials that the Company plans to initiate and other factors listed under “Risk Factors” in the Company’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q that the Company has filed with the U.S. Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

临床研究

2025-01-21

·药事纵横

脂质体药物及其研究进展

许多游离药物具有溶解度低、稳定相差和安全性低在内的诸多特点而限制了其临床应用，纳米技术的进步为使用纳米颗粒进行药物递送创造了无限可能。FDA已经批准了约100种纳米药物上市，通常用作药物输送系统的纳米颗粒有包括脂质体在内的多种体系，它们的粒径范围从几纳米到几百纳米不等。它们通过装载药物使之提高稳定性，克服组织细胞的摄取阻碍，增加药物在体内靶位的富集，提高了药物的安全性与治疗效果。图1：通常用作药物输送系统的纳米颗粒。a 脂质体b 病毒载体c 自组装蛋白d 聚合物纳米颗粒e 金属纳米颗粒f 单壁碳纳米。g树枝状聚合物h 具有核/壳结构的聚苯乙烯涂层磁性颗粒i胶束制剂在Pubmed上以“纳米”、“脂质体”、“药物”为相关关键词来搜索相关研究，纳米相关药物的发文量在2016年后超过脂质体且较为迅速增长，脂质体相关研究中的药物研究占了很大比重，相关发文量都呈现增长模式，预计在不久后会有更多的实验室产品走到工厂或是市场，为各种疾病带来新的治疗机会。图2：以纳米、脂质体和药物相关关键词搜索近10年出现的文章数脂质体纳米平台应用包括生物医学诊断和生物化学中的信号载体、疫苗佐剂和纳米医学中的递送载体等一系列领域。1995年FDA批准Johnson的包载有盐酸阿霉素脂质体抗肿瘤药物Doxil上市，目前美国食品药品监督管理局（FDA）批准了多款脂质体药物上市，适应症也从单一的肿瘤领域拓展到了感染、炎症和镇痛一系列领域。表1：FDA批准上市的脂质体药物表2：新型脂质体（LNP）上市核酸药物/疫苗图3：脂质体/脂质纳米颗粒（LNP，一种新型脂质体）发展时间轴脂质体最早由Bengham在1960年代发现，后来成为最广泛的药物输送系统之一。脂质体是由磷脂和胆固醇组成的球形结构，脂类有天然与人工合成两类，磷脂结构可以带有电荷以便控制其吸收排布。脂质体表面可以带有电荷，由于电荷排斥可以起到稳定脂质体的作用，负电荷的存在（如DMPG）使得脂质体容易被巨噬细胞识别并且能够通过内吞作用进入细胞（速率比中性脂质更快），从而缩短循环时间，而带正电荷的脂质体可能与血液中的阴离子成分（如血浆蛋白）相互作用，被MPS摄取清除。事实上，带正电荷脂质体与带负电的核酸作用而有利于核酸的递送，目前两款新型脂质体技术包载的核酸疫苗（两种阳离子脂质为：SM-102/ALC-0315）便是利用了这个原理而使脂质体在抗击新冠疫情中大放异彩。胆固醇控制磷脂堆积、膜流动性和脂质体表面电荷的能力，脂质体中胆固醇的添加使脂质体在血流中的稳定时间从几分钟延长到了几小时。脂质体也可由单个或多个脂质双分子层组装而成，目前FDA批准上市产品大都为100nm左右大小的单层小囊泡。添加聚合物如聚乙二醇则有延长的其循环的特性（增加脂质体与血液中其他成分的空间位阻），保护负载药物免受灭活或代谢降解，进一步增强稳定性并改善细胞内摄入。脂质体成分中特定靶向成分的添加或进行功能化（使用多糖、糖蛋白或特定受体的配体）来达到靶向的作用（被动靶向主要应用于肿瘤的治疗，依靠于肿瘤血管特性来实现，而主动靶向主要是通过脂质表面的功能化来达到目的）。脂质体产品结构比较复杂，环境或结构的变化可能对脂质体而言是引起其安全性和有效性的挑战，脂质体药物的辅料中一般会添加一些其他成分，如pH缓冲用的柠檬酸/柠檬酸盐体系、渗透压调节用的氯化钠体系、稳定用的糖类。图4：载药脂质体的常见结构以及组分化合物结构示意图目前对于脂质体的制备已经有了许多的技术方法：薄膜水合法、乙醇/乙醚注射法、反相蒸发法、洗涤剂去除法、微流控法、膜挤出法、均质化、超声法、冷冻干燥方法、超临界流体方法等。对于制备完成的脂质体特征（粒径、电位、形态、相位和层状性）的评价则有许多种技术。表3：脂质体参数评估的方法特征技术粒径显微镜、纳米颗粒跟踪分析（NTA）、动态光散射（DLS）、扫描/透射电镜（SEM/TEM）、原子力显微镜（AFM）、低温透射电镜（Cryo-TEM）电位电泳迁移率、DLS 形态 Cryo-TEM、TEM、AFM 相位特性差示扫描量热法（DSC）、X射线衍射（XRD）、热重分析（TGA）层状性 Cryo-TEM 、核磁脂质体的粒径大小影响着药物吸收与分布（体循环、清除、外渗、转运摄取等），理想的粒径在50-200nm范围之内。脂质体所带的净电荷为Zeta电位，电位的大小的绝对值影响着脂质体的稳定性。脂质体电位收到外部环境和离子强度的影响，绝对值较小的脂质体之间排斥力较弱，随时间的推移聚集的可能性较大。显微镜检测是对于脂质体形态检测最直接的方式，其中Cryo-TEM技术检测可以较好的保留脂质体的原始结构，最大限度减小脂质体形态的扭曲变化；AFM技术是一种快速、强大和非侵入性的技术，在脂质体原生条件下提供到高分辨率三维图像。脂质体相行为影响着脂质体的稳定性，DSC是脂质体相行为检测最常见方法。脂质体的层状性影响着药物的释放，Cryo-TEM是最常用的方法，它提供了关于脂质体层状双层厚度和双层的距离等信息。当然，每种技术有自己的优缺点，多种方法联合使用才能从多角度将脂质体的性质进行更加全面的表征。脂质体的疏水外壳包裹着亲水内核，亲水性药物一般包裹在亲水内核中，而疏水药物则包裹在疏水外壳中，目前已经开发出了脂质体的主动载药法（一般发生在脂质体制备完成后阶段）（如Doxil、Marqibo、DaunoXome和Onivyde）和被动载药法（一般发生在脂质体制备过程阶段）（如AmBisome、Visudyne、Arikayce、DepoCyte、DepoDur和Expel）。Vyxeos则采用了组合方式载药（阿糖胞苷和柔红霉素）。目前还有第三种脂质体载药技术---化学偶联技术，具有合适的化学官能团将药物与脂质体连接来控制药物的负载与释放。图5：脂质体的药物装载我们在临床试验资料库（https://clinicaltrials.gov/）上以“脂质体”（liposome）为关键词进行所搜来汇总目前脂质体相关研究的临床情况，2019年后的疫情几年完成的临床数呈下降趋势。我们发现2020年后（近3年）有35项实验已经完成，其中有4项附有研究结果。图6：以“脂质体”（liposome）关键词搜索近10年临床情况表4：临床研究部分信息脂质体的临床研究主要方向是装载药物来对各种疾病进行治疗，研究1的试验调查了伊立替康脂质体和贝伐珠单抗在治疗对铂类治疗（铂类耐药）、复发（复发）或对治疗无反应（难治性）的卵巢癌、输卵管癌或原发性腹膜癌患者中的作用。研究2的目的是确定脂质体布比卡因与盐水在腰椎手术中减少阿片类药物使用的功效，并确定患者报告的结果和住院时间是否存在差异。研究3评估 Exparel、Exparel与盐酸布比卡因混合与盐酸布比卡因联合治疗下肢手术受试者术后镇痛的疗效、安全性和药代动力学。研究4探索Exparel（脂质体布比卡因）在内收肌管阻滞中的有效性（用于全膝关节置换术手术疼痛控制）。通过脂质体改善靶向部位的递送、提高疗效和降低的全身毒性，这是大多数进入临床试验脂质体新药的典型目标。脂质体的出现，以其独特的性质而是许多药物为治疗疾病成为了可能，但是脂质体的组成（成分/纯度）、理化性质、稳定性、表征技术和一系列的临床药学研究（药代/药动/利用度等）仍有许多问题待解决，相信不久的将来在新方法的研究以及新技术的引入会刺激脂质体研究的进一步发展。 REFERENCE 1. Beltrán-Gracia E et al., Cancer Nano. 2019 2. Almeida B et al., Molecules. 2020 3. Gote V et al., Int J Mol Sci. 2023 4. Tenchov R et al., ACS Nano. 2021 药事纵横征稿启事

上市批准核酸药物疫苗信使RNA

100 项与布比卡因相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D07552	布比卡因	N01BB01	DB00297

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
术后疼痛	欧盟	Pacira Ireland Ltd.	2020-11-16
术后疼痛	冰岛	Pacira Ireland Ltd.	2020-11-16
术后疼痛	列支敦士登	Pacira Ireland Ltd.	2020-11-16
术后疼痛	挪威	Pacira Ireland Ltd.	2020-11-16

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
背痛	临床3期	美国	Pacira Biosciences, Inc.	2024-04-30
并发症	临床3期	美国	Pacira Biosciences, Inc.	2024-04-30
恶心	临床3期	美国	Pacira Biosciences, Inc.	2021-10-22
疼痛	临床3期	美国	Pacira Biosciences, Inc.	2021-10-22
腿损伤	临床3期	美国	Pacira Biosciences, Inc.	2020-10-20
关节强直	临床3期	-	Pacira Biosciences, Inc.	2020-06-15
跖骨内翻	临床3期	-	Pacira Biosciences, Inc.	2020-06-15
冠心病	临床3期	美国	Pacira Biosciences, Inc.	2018-11-15
冠状动脉狭窄	临床3期	美国	Pacira Biosciences, Inc.	2018-11-15
二尖瓣关闭不全	临床3期	美国	Pacira Biosciences, Inc.	2018-11-15

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04300231 (CTgov)	临床3期	术后疼痛	160	/hydromorphone 0.05mg/ml+bupivacaine (Thoracic Epidural)	夢願壓築廠繭夢鬱艱鏇(鹽蓋餘鑰齋顧膚願鹹餘) = 憲襯糧顧網膚獵窪鹹憲夢鹽餘膚襯窪餘鬱餘繭 (艱鹽襯齋獵製遞壓願獵, 壓遞廠遞蓋築鹹廠願鑰 ~ 範餘鑰齋壓鹽選獵繭鬱) 更多	-	2025-02-10
				injectable saline+Liposomal bupivacaine+bupivacaine (Rectus Sheath Block)	夢願壓築廠繭夢鬱艱鏇(鹽蓋餘鑰齋顧膚願鹹餘) = 選鏇餘鹽觸選憲壓襯醖夢鹽餘膚襯窪餘鬱餘繭 (艱鹽襯齋獵製遞壓願獵, 衊鑰鑰獵襯壓獵齋襯鹽 ~ 築鬱衊網糧齋鹽夢鏇觸) 更多
NCT04867369 (CTgov)	临床4期	肌腱病	160	Bupivacaine 20mL 0.5% (Pecs II Block)	鹽觸壓鑰簾網網獵選繭(選膚窪遞積糧鹹獵鏇窪) = 鏇範遞網網繭簾範築窪餘積範網鹹蓋築餘壓醖 (襯齋遞壓選餘選築鹽鹽, 蓋鬱醖繭製廠範製願壓 ~ 齋選餘夢選構鑰衊淵願) 更多	-	2024-12-13
				Bupivacaine up to 15mL 0.25% (Surgical Infiltration)	鹽觸壓鑰簾網網獵選繭(選膚窪遞積糧鹹獵鏇窪) = 艱簾齋淵壓選艱願糧齋餘積範網鹹蓋築餘壓醖 (襯齋遞壓選餘選築鹽鹽, 繭艱願夢願糧鬱淵簾網 ~ 膚觸糧衊廠積淵襯製範) 更多
NCT04996251 (CLAPPS, CTgov)	临床4期	术后疼痛	129	Bupivacaine Injection (Subcutaneous Infiltration Pre-incision)	範製網顧鹽醖醖鹹鹽衊(廠衊齋夢艱顧糧鏇顧遞) = 糧鏇繭網膚鑰製鏇獵觸窪鹹淵膚網壓襯廠遞淵 (齋襯築製醖網鬱簾網願, 鏇窪夢壓繭選膚膚顧構 ~ 獵遞艱夢製淵顧顧夢積) 更多	-	2024-12-10
				Bupivacaine Injection (Subcutaneous Infiltration Post-incision)	範製網顧鹽醖醖鹹鹽衊(廠衊齋夢艱顧糧鏇顧遞) = 鹽鏇積膚餘繭鑰醖鹹鑰窪鹹淵膚網壓襯廠遞淵 (齋襯築製醖網鬱簾網願, 醖遞獵夢選淵廠顧壓範 ~ 簾網鹹顧範積鑰觸繭構) 更多
NCT04364867 (CTgov)	临床4期	术后疼痛	102	Exparel (Exparel)	壓鑰積齋簾齋醖鏇繭憲(積齋夢鹹繭憲窪廠夢淵) = 糧獵築範餘觸膚壓膚範鏇顧範醖選鑰糧簾鏇憲 (衊構廠顧鬱齋鑰襯顧獵, 觸遞襯餘鹹醖遞衊蓋淵 ~ 襯鹹範範淵窪製壓淵構) 更多	-	2024-11-26
				Pain Pump (Pain Pump)	壓鑰積齋簾齋醖鏇繭憲(積齋夢鹹繭憲窪廠夢淵) = 願襯網鏇鹹觸觸蓋築憲鏇顧範醖選鑰糧簾鏇憲 (衊構廠顧鬱齋鑰襯顧獵, 襯齋選淵糧選構遞蓋壓 ~ 網蓋獵夢鑰齋艱網餘選) 更多
NCT04928339 (CTgov)	临床4期	-	100	Bupivacaine Injection (PIFB Intervention)	遞構鑰窪齋範淵範艱遞(簾廠網襯獵襯鬱夢遞艱) = 鹽願鑰糧簾膚蓋淵襯獵範窪衊鹽鬱齋鹹範鑰鏇 (餘製淵範艱積淵範艱襯, 艱選製繭選鏇蓋簾鏇廠 ~ 範鹹齋遞觸遞廠醖範鏇) 更多	-	2024-11-19
				saline (Saline Control)	遞構鑰窪齋範淵範艱遞(簾廠網襯獵襯鬱夢遞艱) = 蓋鏇鑰膚積膚襯遞艱壓範窪衊鹽鬱齋鹹範鑰鏇 (餘製淵範艱積淵範艱襯, 鬱範獵艱醖糧衊選選願 ~ 顧顧衊選積遞繭憲蓋鹹) 更多
NCT05068661 (CTgov)	临床4期	产痛	101	Ropivacaine 0.1% Injectable Solution+Bupivacaine 0.25% Injectable Solution (Combined Spinal Epidural)	艱衊淵餘餘鑰淵鹽餘衊(網繭簾憲壓鬱蓋淵廠鬱) = 願網繭範醖鏇蓋遞選鏇獵繭糧製獵壓窪範願遞 (構鬱網膚襯顧遞積衊衊, 簾製築選築夢網範壓鹽 ~ 醖糧繭醖選夢夢築齋窪) 更多	-	2024-11-06
				Ropivacaine 0.1% Injectable Solution (Dural Puncture Epidural)	艱衊淵餘餘鑰淵鹽餘衊(網繭簾憲壓鬱蓋淵廠鬱) = 願網蓋餘鏇衊蓋製夢鏇獵繭糧製獵壓窪範願遞 (構鬱網膚襯顧遞積衊衊, 衊憲淵壓鑰鹹窪壓廠製 ~ 鹽壓壓網窪艱廠範範網) 更多
NCT04777591 (Pubmed \| Plast Reconstr Surg)	临床4期	-	117	Bupivacaine and Epinephrine TAP block	鹽壓蓋築齋繭糧網齋糧(糧襯製鏇窪餘繭網範獵) = 鑰齋壓憲齋窪鬱選憲網淵築憲觸積網觸糧廠觸 (夢餘鑰築鬱襯鏇網觸觸 ) 更多	不佳	2024-10-01
				Liposomal Bupivacaine, Bupivacaine, and Epinephrine TAP block	鹽壓蓋築齋繭糧網齋糧(糧襯製鏇窪餘繭網範獵) = 選窪鑰構淵鏇簾鹹鬱鬱淵築憲觸積網觸糧廠觸 (夢餘鑰築鬱襯鏇網觸觸 ) 更多
NCT05767749 (CTgov)	临床4期	麻醉	75	Ropivacaine+Epinephrine+Lidocaine (Lidocaine+Epinephrine (vs Ropivacaine))	顧顧齋廠壓鹽餘夢襯構(膚繭網夢膚鹽獵繭範襯) = 餘顧齋糧衊鏇獵獵憲願鹽窪顧網鏇獵膚遞膚衊 (糧簾窪蓋壓蓋遞遞鑰鏇, 壓蓋選廠餘範壓築衊網 ~ 衊憲艱選蓋夢餘鏇範襯) 更多	-	2024-09-19
				Ropivacaine+Epinephrine+Lidocaine (Ropivacaine (vs Lidocaine+Epinephrine))	顧顧齋廠壓鹽餘夢襯構(膚繭網夢膚鹽獵繭範襯) = 憲壓顧範鹽衊製窪襯築鹽窪顧網鏇獵膚遞膚衊 (糧簾窪蓋壓蓋遞遞鑰鏇, 鹹築淵壓選願觸蓋網簾 ~ 願網鑰簾積膚觸築壓餘) 更多
NCT03859024 (CTgov)	临床4期	尿道狭窄 \| 术后疼痛	48	Acetaminophen+Ibuprofen 800 mg+Oxycodone (Standard Protocol)	願獵鬱願鏇醖繭艱築糧(積壓觸鑰範顧遞選廠夢) = 淵膚壓鏇膚願觸蓋夢夢構糧鏇齋衊壓夢製憲膚 (顧網製選積襯艱繭構艱, 遞鏇糧範製繭願蓋艱襯 ~ 夢艱廠觸願鹽鹽顧鹽選) 更多	-	2024-09-19
				Acetaminophen+Ibuprofen 800 mg+celebrex+Dexamethasone+Oxycodone+Bupivacaine+Gabapentin (Enhanced Recovery Protocol)	願獵鬱願鏇醖繭艱築糧(積壓觸鑰範顧遞選廠夢) = 襯夢製鏇衊獵積齋鬱築構糧鏇齋衊壓夢製憲膚 (顧網製選積襯艱繭構艱, 顧鑰淵艱遞餘憲選廠顧 ~ 窪顧齋鏇積鏇蓋醖廠襯) 更多
NCT03266926 (Pubmed \| J Minim Invasive Gynecol)	N/A	-	210	Estrogen-soaked vaginal packs	選鏇選鏇繭獵遞鏇積艱(糧繭鏇衊遞簾糧壓艱願) = 繭艱襯築夢積糧壓選觸蓋構齋餘襯鹹齋鏇簾窪 (鏇觸遞製鹽窪餘獵窪艱 ) 更多	不佳	2024-09-01
				Bupivacaine-soaked vaginal packs	選鏇選鏇繭獵遞鏇積艱(糧繭鏇衊遞簾糧壓艱願) = 鹽顧顧醖蓋壓餘鏇遞選蓋構齋餘襯鹹齋鏇簾窪 (鏇觸遞製鹽窪餘獵窪艱 ) 更多